Clinical Utility of Thyroglobulin Antibody (TgAb) Measurements for Patients with Differentiated Thyroid Cancers (DTC)

Spencer, Carole A.

doi:10.1210/jc.2011-1740

Cited by 217 publications

(184 citation statements)

References 121 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…The level of serum Tg is a well-known tumor marker for the patients with DTC, and we showed that only about 1% of DTC patients who had a serumstimulated Tg level !1 ng/ml at 1 year after initial treatment developed recurrent disease (19,20). However, the prognostic value of serum Tg measurement was limited in the presence of TgAb because of false-negative results owing to TgAb interference with immunometric assay (14,21). We also suggested that the level of serum TgAb and a change in the serum TgAb concentration could be a prognostic indicator during the early postoperative period.…”

Section: Discussionmentioning

confidence: 93%

“…The prevalence of positive serum TgAb in patients with DTC is 10-25% and is about twofold higher than in the general population (14,21). The timing of TgAb measurement is likely to affect the prevalence of positive serum TgAb level because TgAb decreases and eventually disappears as it removes the antigenic stimulus from Tg after initial therapy (22).…”

Section: Discussionmentioning

confidence: 99%

“…This system has been validated in three large cohort studies in the United States and Brazil (11,12,13). However, this dynamic risk assessment did not take into consideration the status of serum anti-Tg antibody (TgAb) even though 10-25% of patients with DTC have a positive serum TgAb level (14). Delayed risk stratification, proposed by Castagna et al (15), also did not include patients with a positive serum TgAb level.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma

Jeon

Kim

Park

et al. 2014

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: A new risk stratification system was proposed to estimate the risk of recurrence in patients with differentiated thyroid carcinoma (DTC) using the response to initial therapy. Here, we describe the modified dynamic risk stratification system, which takes into consideration the status of serum anti-Tg antibody (TgAb), and validate this system for assessing the risk of recurrence in patients with DTC. Patients and methods: Patients who underwent total thyroidectomy with radioiodine remnant ablation due to DTC between 2000 and 2005 were included. We classified patients into four groups based on the response to the initial therapy ('excellent', 'acceptable', 'biochemical incomplete', and 'structural incomplete' response). Results: The median follow-up period of 715 patients with DTC was 8 years. The response to initial therapy was an important risk predictor for recurrent/persistent DTC. The relative risks (95% CI) of recurrence were 16.5 (6.3-43.0) in the 'acceptable response ' group, 41.3 (15.4-110.8) in the 'biochemical incomplete response' group, and 281.2 (112.9-700.5) in the 'structural incomplete response' group compared with the 'excellent response' group (P!0.001, P!0.001, and P!0.001 respectively). The disease-free survival rate of the 'excellent response' group to initial therapy was 98.3% whereas that of the 'structural incomplete response' group was only 6.8%. Conclusions: Our study validates the usefulness of the modified dynamic risk stratification system including the status of serum TgAb for predicting recurrent/persistent disease in patients with DTC. Personalized risk assessment using the response to initial therapy could be useful for the follow-up and management of patients with DTC.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma

Jeon

Kim

Park

et al. 2014

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…This could be also supported by the observation that approximately twofold higher concentration of anti-Tg and anti-TPO antibodies can be found in the peripheral blood of PTC patients compared to the general population [41]. The induced antitumor immune response should be due to the presence of papillary thyroid microcarcinomas that share with PTC a similar gene expression profile [42].…”

Section: Cellular and Humoral Immune Responsementioning

confidence: 88%

Thyroid Autoimmunity and Cancer

Felicetti¹,

Catalano²,

Fortunati³

2017

Frontiers of Hormone Research

View full text Add to dashboard Cite

Cancer and autoimmune diseases are often associated in the same individual. The functional link between immune system and cancer development is only partially known. Even though the immune system can control the development of cancer through immune surveillance, cancer cell itself can escape immune surveillance. Actually, it is debated whether autoimmune diseases have to be regarded as cancer cause or its consequence.In particular, autoimmune thyroiditis and thyroid cancer (in particular, papillary thyroid cancer) are a fascinating model of this complex relationship. In the present review, we describe what has been reported by now in literature about autoimmune thyroiditis and papillary thyroid cancer, and on the basis of available data, we try to clarify the present knowledge.

show abstract

“…La cirugía puede iniciar o propiciar la aparición de novo de Ac-anti-Tg, que tienden a declinar en el curso de meses. Los pacientes pueden no alcanzar un estado negativo de Ac-anti-Tg durante el primer año postoperatorio e incluso exhibir un aumento (o la aparición de novo) durante los seis meses posteriores al tratamiento con yodo 131 cuando hay liberación de Tg secundaria a daño radiolítico del tejido tiroideo 59 . Para un seguimiento eficaz de los Ac-anti-Tg a largo plazo, es fundamental utilizar un método sensible cada 6-12 meses.…”

Section: B a Eunclassified

La medicina nuclear y el cáncer diferenciado de tiroides

Medina-Ornelas¹,

García-Pérez²,

Granados-García³

2022

GAMO

View full text Add to dashboard Cite

Gaceta Mexicana de Oncologia. 2017;16(4):239-248 resumen: Los afectados por cáncer diferenciado de tiroides (CDT) suelen tener un curso clí-nico favorable, pero algunos pueden mostrar un curso agresivo con recaídas. El tratamiento óptimo aún es controvertido, en especial respecto a la extensión de la cirugía, las indicaciones de radioyodo y la supresión de hormona estimuladora del tiroides (TSH). La evaluación correcta de los riesgos facilita un enfoque selectivo de la terapia. Presentamos una revisión del papel de la medicina nuclear en la evaluación, tratamiento y seguimiento de pacientes afectados por esta interesante enfermedad. (creativecommons.org/licenses/by-nc-nd/4.0/). abstract Those affected by differentiated thyroid cancer tend to have a favorable clinical course, but some may show an aggressive course with relapses. The optimal treatment is still controversial, especially regarding the extent of surgery, indications for radioiodine and suppression of thyroid-stimulating hormone. Correct risk assessment facilitates a selective approach to therapy. We present a review of the role of nuclear medicine in the evaluation, treatment and follow-up of patients affected by this interesting disease. PalaBraS ClaVECáncer de tiroides; Radioyodo; Medicina nuclear; Tratamiento KEY WorDSThyroid cancer; Radioiodine; Nuclear medicine; Treatment introDuCCión Según Globocan, en 2012 en México ocurrieron 3,036 casos de cáncer de tiroides (725 en hombres y 2,311 en mujeres), que constituyeron el 2.1% del total de neoplasias malignas 1 . El CDT representa al menos el 85% de los casos e incluye los tipos papilar, folicular y de células de Hürtle. El cáncer papilar, el tipo más frecuente, se asocia a una excelente supervivencia, pero algunos pacientes tienen un curso clínico menos favorable, con metástasis o recaídas que afectan a los ganglios linfáticos cervicales y, con menor frecuencia, a los pulmones y el hueso 2,3 . La medicina nuclear se sirve de las peculiaridades de la fisiopatología del CDT y juega un papel muy importante tanto en el tratamiento adyuvante como en el seguimiento y manejo de las recaídas. El tratamiento debe ser el más eficaz posible, con las menores secuelas y el menor costo; por ello se enfatiza el tratamiento individualizado, acorde al tipo histológico, la extensión de la enfermedad y el riesgo de recaída. YoDo 131El yodo 131 ([131]I o radioyodo) es producido en un reactor nuclear mediante la irradiación neutrónica de dióxido de telurio durante la fisión del uranio. Su vida media física es de 8.02 días. Los átomos del yodo 131 emiten partículas β con

show abstract

Clinical Utility of Thyroglobulin Antibody (TgAb) Measurements for Patients with Differentiated Thyroid Cancers (DTC)

Cited by 217 publications

References 121 publications

Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma

Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma

Thyroid Autoimmunity and Cancer

La medicina nuclear y el cáncer diferenciado de tiroides

Contact Info

Product

Resources

About